
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Glysite™ Explorer in situ PLA Glycan Detection Kit

Vector Laboratories and Navinci announced the launch of the Glysite™ Explorer in situ PLA Glycan Detection Kit to Advance Functional Proteomics Research

FDA Approves Biocon Biologics' Kirsty™: The First Interchangeable Rapid-Acting Insulin Aspart in the U.S.

FDA Approves Updated Label for Kisunla, Featuring New Dosing to Significantly Reduce ARIA-E Risk in Alzheimer's
STOBOCLO® and OSENVELT®

Celltrion USA Launches Denosumab Biosimilars STOBOCLO and OSENVELT in U.S.

MiNK Therapeutics' Allogeneic iNKT Cell Therapy Achieves Complete Remission in Metastatic Testicular Cancer

AbbVie and IGI Partner on ISB 2001: A Novel Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Recursion Takes Full Control of REV102: Accelerating AI-Driven Oral Therapy for Hypophosphatasia
ZELSUVMI™ (berdazimer)

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

Miraterra acquires Trace Genomics, an Ag-tech company to unlock measurement and insights across soil, plants, and food
QX Continuum™ ddPCR system and QX700™ series

Bio-Rad launches QX Continuum™ ddPCR System and QX700™ Series, Expanding Droplet Digital PCR Portfolio

EMA Grants Nurix Therapeutics' Bexobrutideg (NX-5948) Orphan Drug Designation for Waldenström Macroglobulinemia

Hope for Rare Brain Cancers: MB-101 (CAR T-cells) from Mustang Bio Gains Orphan Drug Status for Astrocytomas and Glioblastoma

ZEGFROVY® Gains FDA Accelerated Approval for NSCLC with EGFR Exon 20 Insertion Mutations with Thermo Fisher's Oncomine™ Dx as companion diagnostic test

FDA Accelerates Approval of Regeneron's Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma
Proteograph® Product Suite

Seer launches Proteograph® Product Suite at ASMS 2025, Revolutionizing Proteomics Scale & Efficiency

FDA Approves Gamifant: A Groundbreaking Treatment for Macrophage Activation Syndrome in Still's Disease

FDA Approves Takeda's GAMMAGARD LIQUID ERC: A Unique, Low IgA Immunoglobulin Therapy for Easier Patient Use
ProxiMeta™

Phase Genomics launches ProxiMeta Bundles for Simplified Genome-Resolved Metagenomics
Health Insights test

Genomics Advances Global Roll-Out of Predictive Clinical Tool, Health Insights

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Klotho Neurosciences Partners with Okinawa Longevity Experts to Analyze Klotho Gene in Longest-Lived Population

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

ORYZON Advances Vafidemstat for Borderline Personality Disorder with FDA Phase III Protocol Submission

Fabric Genomics and Galatea Bio partner to deliver comprehensive genetic testing for common diseases

Updated Interim Data from Passage Bio's upliFT-D Study Highlights One-Time Gene Therapy for Frontotemporal Dementia

Astrazeneca's Datroway Approved in US to Treat Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Redosable, Eye Drop Gene Therapy KB803 Enters Phase 3 with First Patient Dosed by Krystal Biotech for Dystrophic Epidermolysis Bullosa Eye Complications

Symbiotic.blue Unites Oxford & Cambridge Science with Biotech Leadership to Reimagine AI Drug Discovery

FDA Approves Cycle Pharmaceuticals' HARLIKU™ (nitisinone) Tablets, a Breakthrough for Ultra-Rare Genetic Metabolic Disorder Alkaptonuria (AKU)

Incyte's Monjuvi® (tafasitamab-cxix) Gains FDA Approval for Relapsed/Refractory Follicular Lymphoma

Gilead's Yeztugo® (Lenacapavir) Becomes First and Only FDA-Approved 6-Month HIV Prevention Option

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Capricor Therapeutics Gains Orphan Drug Status for Becker Muscular Dystrophy, Advances Duchenne Program
SAIR (Structurally Augmented IC50 Repository)

SandboxAQ Launches SAIR (Structurally Augmented IC50 Repository) to Advance Drug Discovery
AI-powered PanOmiQ platform

BioAro launches AI-Driven PanOmiQ with Ultrafast Whole Genome Sequencing Analysis Technology

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sanofi and Regeneron Announce Positive EVEREST Trial Results for Severe CRSwNP with Coexisting Asthma

Intellia Announces One-Time Gene-Editing Treatment Lonvo-z Shows Durable Three-Year Efficacy in HAE Patients
VISTA™ platform

Myllia Biotechnology launches the VISTA™ platform to enable genome wide CRISPR screens in Primary Human Macrophages and Dendritic Cells
Mimix™ reference standards for IVD

Revvity announces the launch of three Mimix™ reference standards for IVD use

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD)

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

U.S. FDA Approves UroGen’s ZUSDURI™ as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in CharcotMarie-Tooth disease Type 2S

George Medicines announces FDA approval of WIDAPLIK™, a new single pill combination treatment for hypertension in adults

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Integrated PRS, CAD (CAD iPRS)

MyOme Launches Integrated Risk Tool for Coronary Artery Disease (CAD iPRS)
PromoterAI

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
ClearPath™ Dried Blood Spot Test

Savara Launches the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
StrataRisk™

Galatea Bio Launches Scalable Polygenic Risk Assessment tool, StrataRisk™ for Common Diseases